VitriVax Raises 87 Million Dollars for Lyme Vaccine and Formulation

VitriVax announced an $87 million Series C on November 18 to advance a Lyme disease vaccine candidate into first-in-human testing and broaden its thermostable vaccine formulation platform. It is new private capital with a…




